Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | HPGD | P15428 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | HTR2C | P28335 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | HTR1A | P08908 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | DRD2 | P14416 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.82 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.82 |
| ▸ | LMNA | P02545 | 2/20 | 0.82 |
| ▸ | MAPT | P10636 | 2/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.82 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.82 |
| ▸ | MEN1 | O00255 | 1/20 | 0.82 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.82 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.82 |
| ▸ | DRD1 | P21728 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Altanserin SCHEMBL30136524 | 1.00 | HTR2A (1.00) | HTR2ACYP3A4HPGDCYP2D6HTR2C | |
| Altanserin SCHEMBL12629110 | 1.00 | HTR2A (1.00) | HTR2ACYP3A4HPGDCYP2D6HTR2C | |
| Altanserin SCHEMBL30136526 | 1.00 | HTR2A (1.00) | HTR2ACYP3A4HPGDCYP2D6HTR2C | |
| Altanserin SCHEMBL15662949 | 0.99 | HTR2A (1.00) | HTR2ACYP3A4HPGDCYP2D6HTR2C | |
| SCHEMBL11015897 | 0.94 | HTR2A (0.89) | HTR2ACYP3A4HPGDCYP2D6HTR2C | |
| Altanserin SCHEMBL124036 | 0.94 | HTR2A (0.88) | HTR2ACYP3A4HPGDCYP2D6HTR2C | |
| Altanserin SCHEMBL124037 | 0.94 | HTR2A (0.88) | HTR2ACYP3A4HPGDCYP2D6HTR2C | |
| SCHEMBL21104614 | 0.90 | HTR2A (0.82) | HTR2ACYP3A4HPGDCYP2D6HTR2C | |
| SCHEMBL14544003 | 0.90 | HTR2A (0.82) | HTR2ACYP3A4HPGDCYP2D6HTR2C | |
| Ketanserin SCHEMBL29361038 | 0.90 | HTR2A (1.00) | HTR2ACYP3A4HPGDCYP2D6HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 539 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4725483-A1 | COMBINATION COMPRISING AT LEAST ONE 5-HT2A RECEPTOR ANTAGONIST AND AT LEAST ONE 5-HT3 RECEPTOR ANTAGONIST AND ITS MEDICAL USE | Université de Bordeaux (FR) | 2026-04-15 | — | — | EP | claimed |
| EP-4680244-A1 | SEROTONIN 5HT2A RECEPTOR ANTAGONIST FOR USE IN TREATING SIDE EFFECTS RESULTING FORM MU OPIOID RECEPTOR AGONIST OVERDOSE | Norwegian University Of Life Sciences (NO) | 2026-01-21 | — | — | EP | claimed |
| US-12514937-B2 | Methods for detecting CCR2 receptors | WASHINGTON UNIVERSITY (US) | 2026-01-06 | — | — | US | claimed |
| US-20260000641-A1 | ISOTOPICALLY ENRICHED ANALOGS OF 5,6-METHYLENEDIOXY-2-AMINOINDANE (IMDAI) | TERRAN BIOSCIENCES INC (US) | 2026-01-01 | — | — | US | claimed |
| WO-2025264860-A2 | METHODS OF TREATING POST-COVID AIRWAY DISEASE | YALE UNIVERSITY (US) | 2025-12-26 | — | — | WO | claimed |
| WO-2025226286-A1 | SYSTEMS AND METHODS FOR SIMULTANEOUS IMAGING OF MULTIPLE POSITRON EMISSION TOMOGRAPHY (PET) TRACERS | MULTIF UNCTIONAL IMAGING LLC (US) | 2025-10-30 | — | — | WO | claimed |
| US-20250329024-A1 | SYSTEMS AND METHODS FOR SIMULTANEOUS IMAGING OF MULTIPLE POSITRON EMISSION TOMOGRAPHY (PET) TRACERS | MultiFunctional Imaging LLC (US) | 2025-10-23 | — | — | US | claimed |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | claimed |
| EP-4547250-A1 | METHODS AND COMPOSITIONS RELATING TO CONTROLLING PSYCHEDELIC EFFECTS WITH SEROTONIN RECEPTOR MODULATORS | Terran Biosciences Inc. (US) | 2025-05-07 | — | — | EP | claimed |
| US-20250136548-A1 | FUNCTIONALIZED ALKYLAMINES | TERRAN BIOSCIENCES INC (US) | 2025-05-01 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101677971-A | The combination of 5-HT2A inverse agonist and antagonist and antipsychotic drug | ACADIA PHARM INC | 2010-03-24 | — | — | CN | claimed |
| EP-2134330-A2 | COMBINATIONS OF 5-HT2A INVERSE AGONISTS AND ANTAGONISTS WITH ANTIPSYCHOTICS | Acadia Pharmaceuticals Inc. (US) | 2009-12-23 | — | — | EP | claimed |
| WO-2009108798-A1 | METHOD FOR TREATING PAIN SYNDROME AND OTHER DISORDERS | VM DISCOVERY INC. (US) | 2009-09-03 | — | — | WO | claimed |
| US-20090053329-A1 | COMBINATIONS OF 5-HT2A INVERSE AGONISTS AND ANTAGONISTS WITH ANTIPSYCHOTICS | ACADIA PHARMACEUTICALS, INC. (US) | 2009-02-26 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| WO-2008116024-A2 | COMBINATIONS OF 5-HT2A INVERSE AGONISTS AND ANTAGONISTS WITH ANTIPSYCHOTICS | ACADIA PHARMACEUTICALS INC. (US) | 2008-09-25 | — | — | WO | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260000641-A1 | ISOTOPICALLY ENRICHED ANALOGS OF 5,6-METHYLENEDIOXY-2-AMINOINDANE (IMDAI) | DRD2, HTR1D, DRD1 | HTR2A 7/4885CYP3A4 2054/4885HPGD 1740/4885 |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | HTR2A, HTR5A, HTR6 | HTR2A 1/4885CYP3A4 1995/4885HPGD 965/4885 |
| US-20250136548-A1 | FUNCTIONALIZED ALKYLAMINES | BDNF, HTR2A, NTRK2 | HTR2A 2/4885CYP3A4 4707/4885HPGD 2941/4885 |
| US-20090053329-A1 | COMBINATIONS OF 5-HT2A INVERSE AGONISTS AND ANTAGONISTS WITH ANTIPSYCHOTICS | HTR2A, HTR3A, HTR1A | HTR2A 1/4885CYP3A4 809/4885HPGD 2287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.